1-20 of 24
Robert M. Sharkey
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Available to Purchase
Jhanelle E. Gray, Rebecca S. Heist, Alexander N. Starodub, D. Ross Camidge, Ebenezer A. Kio, Gregory A. Masters, W. Thomas Purcell, Michael J. Guarino, Jamal Misleh, Charles J. Schneider, Bryan J. Schneider, Allyson Ocean, Tirrell Johnson, Leena Gandhi, Kevin Kalinsky, Ronald Scheff, Wells A. Messersmith, Serengulam V. Govindan, Pius P. Maliakal, Boyd Mudenda, William A. Wegener, Robert M. Sharkey, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (19): 5711–5719.
https://doi.org/10.1158/1078-0432.CCR-17-0933
Published: 01 October 2017
View articletitled, Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
Open the PDF for Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan in another window
Includes: Supplementary data
Journal Articles

Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2–wild-type Triple-Negative Breast Cancer

Free
Thomas M. Cardillo, Robert M. Sharkey, Diane L. Rossi, Roberto Arrojo, Ali A. Mostafa, David M. Goldenberg
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (13): 3405–3415.
https://doi.org/10.1158/1078-0432.CCR-16-2401
Published: 02 July 2017
View articletitled, Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2–wild-type Triple-Negative Breast Cancer
Open the PDF for Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2–wild-type Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A32: Pretargeted immunoPET of CEA-expressing in intraperitoneal human colonic tumor xenografts in nude mice

Free
Rafke Schoffelen, Robert M. Sharkey, Gerben M. Franssen, David M. Goldenberg, William J. McBride, Edmund A. Rossi, Chien-Hsing Chang, Peter Laverman, Winette T.A. Graaf, Wim J.G. Oyen, Otto C. Boerman
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (7_Supplement): A32.
https://doi.org/10.1158/1078-0432.TCME10-A32
Published: 02 February 2016
View articletitled, Abstract A32: Pretargeted immunoPET of CEA-expressing in intraperitoneal human colonic tumor xenografts in nude mice
Journal Articles

Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)

Available to Purchase
Robert M. Sharkey, William J. McBride, Thomas M. Cardillo, Serengulam V. Govindan, Yang Wang, Edmund A. Rossi, Chien-Hsing Chang, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (22): 5131–5138.
https://doi.org/10.1158/1078-0432.CCR-15-0670
Published: 12 November 2015
View articletitled, Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)
Open the PDF for Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan) in another window
Includes: Supplementary data
Journal Articles

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

Available to Purchase
Alexander N. Starodub, Allyson J. Ocean, Manish A. Shah, Michael J. Guarino, Vincent J. Picozzi, Jr, Linda T. Vahdat, Sajeve S. Thomas, Serengulam V. Govindan, Pius P. Maliakal, William A. Wegener, Steven A. Hamburger, Robert M. Sharkey, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17): 3870–3878.
https://doi.org/10.1158/1078-0432.CCR-14-3321
Published: 31 August 2015
View articletitled, First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Open the PDF for First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial

Available to Purchase
Seza A. Gulec, Steven J. Cohen, Kenneth L. Pennington, Lionel S. Zuckier, Ralph J. Hauke, Heather Horne, William A. Wegener, Nick Teoh, David V. Gold, Robert M. Sharkey, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (12): 4091–4100.
https://doi.org/10.1158/1078-0432.CCR-10-2579
Published: 15 June 2011
View articletitled, Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial
Open the PDF for Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial in another window
Journal Articles

Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

Available to Purchase
Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey, Preeti Trisal, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3157–3169.
https://doi.org/10.1158/1078-0432.CCR-10-2939
Published: 15 May 2011
View articletitled, Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
Open the PDF for Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys in another window
Includes: Supplementary data
Journal Articles

Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab)

Available to Purchase
M. Jules Mattes, Robert M. Sharkey, Habibe Karacay, Myron S. Czuczman, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19): 6154–6160.
https://doi.org/10.1158/1078-0432.CCR-08-0404
Published: 30 September 2008
View articletitled, Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab)
Open the PDF for Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab) in another window
Journal Articles

A Divalent Hapten-Peptide Induces Apoptosis in Human Non–Hodgkin Lymphoma Cell Lines Targeted by Anti-CD20 × Anti-Hapten Bispecific Antibodies

Available to Purchase
Pierre-Yves Brard, Habibe Karacay, Rhona Stein, Robert M. Sharkey, M. Jules Mattes, Chien-Hsing Chang, Edmund A. Rossi, William J. McBride, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5564s–5571s.
https://doi.org/10.1158/1078-0432.CCR-07-1204
Published: 17 September 2007
View articletitled, A Divalent Hapten-Peptide Induces Apoptosis in Human Non–Hodgkin Lymphoma Cell Lines Targeted by Anti-CD20 × Anti-Hapten Bispecific Antibodies
Open the PDF for A Divalent Hapten-Peptide Induces Apoptosis in Human Non–Hodgkin Lymphoma Cell Lines Targeted by Anti-CD20 × Anti-Hapten Bispecific Antibodies in another window
Journal Articles

Bispecific Antibody Pretargeting of Radionuclides for Immuno–Single-Photon Emission Computed Tomography and Immuno–Positron Emission Tomography Molecular Imaging: An Update

Available to Purchase
Robert M. Sharkey, Habibe Karacay, William J. McBride, Edmund A. Rossi, Chien-Hsing Chang, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5577s–5585s.
https://doi.org/10.1158/1078-0432.CCR-07-1087
Published: 17 September 2007
View articletitled, Bispecific Antibody Pretargeting of Radionuclides for Immuno–Single-Photon Emission Computed Tomography and Immuno–Positron Emission Tomography Molecular Imaging: An Update
Open the PDF for Bispecific Antibody Pretargeting of Radionuclides for Immuno–Single-Photon Emission Computed Tomography and Immuno–Positron Emission Tomography Molecular Imaging: An Update in another window
Journal Articles

Bispecific Antibody Pretargeting of Tumor Neovasculature for Improved Systemic Radiotherapy of Solid Tumors

Available to Purchase
Dieter Moosmayer, Dietmar Berndorff, Chien-Hsing Chang, Robert M. Sharkey, Axel Rother, Sandra Borkowski, Edmund A. Rossi, William J. McBride, Thomas M. Cardillo, David M. Goldenberg, Ludger M. Dinkelborg
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (18): 5587–5595.
https://doi.org/10.1158/1078-0432.CCR-06-0210
Published: 25 September 2006
View articletitled, Bispecific Antibody Pretargeting of Tumor Neovasculature for Improved Systemic Radiotherapy of Solid Tumors
Open the PDF for Bispecific Antibody Pretargeting of Tumor Neovasculature for Improved Systemic Radiotherapy of Solid Tumors in another window
Journal Articles

Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft

Available to Purchase
Habibe Karacay, Pierre-Yves Brard, Robert M. Sharkey, Chien-Hsing Chang, Edmund A. Rossi, William J. McBride, Dan R. Ragland, Ivan D. Horak, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7879–7885.
https://doi.org/10.1158/1078-0432.CCR-05-1246
Published: 08 November 2005
View articletitled, Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft
Open the PDF for Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft in another window
Journal Articles

Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods

Available to Purchase
Robert M. Sharkey, Habibe Karacay, Thomas M. Cardillo, Chien-Hsing Chang, William J. McBride, Edmund A. Rossi, Ivan D. Horak, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (19): 7109s–7121s.
https://doi.org/10.1158/1078-0432.CCR-1004-0009
Published: 03 October 2005
View articletitled, Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods
Open the PDF for Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods in another window
Journal Articles

Pretargeting of Carcinoembryonic Antigen–Expressing Cancers with a Trivalent Bispecific Fusion Protein Produced in Myeloma Cells

Available to Purchase
Edmund A. Rossi, Chien-Hsing Chang, Michele J. Losman, Robert M. Sharkey, Habibe Karacay, William McBride, Thomas M. Cardillo, Hans J. Hansen, Zhengxing Qu, Ivan D. Horak, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (19): 7122s–7129s.
https://doi.org/10.1158/1078-0432.CCR-1004-0020
Published: 03 October 2005
View articletitled, Pretargeting of Carcinoembryonic Antigen–Expressing Cancers with a Trivalent Bispecific Fusion Protein Produced in Myeloma Cells
Open the PDF for Pretargeting of Carcinoembryonic Antigen–Expressing Cancers with a Trivalent Bispecific Fusion Protein Produced in Myeloma Cells in another window
Journal Articles

Improved Targeting of Pancreatic Cancer: Experimental Studies of a New Bispecific Antibody, Pretargeting Enhancement System for Immunoscintigraphy

Available to Purchase
Thomas M. Cardillo, Habibe Karacay, David M. Goldenberg, Dion Yeldell, Chien-Hsing Chang, David E. Modrak, Robert M. Sharkey, David V. Gold
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (10): 3552–3561.
https://doi.org/10.1158/1078-0432.CCR-03-0340
Published: 24 May 2004
View articletitled, Improved Targeting of Pancreatic Cancer: Experimental Studies of a New Bispecific Antibody, Pretargeting Enhancement System for Immunoscintigraphy
Open the PDF for Improved Targeting of Pancreatic Cancer: Experimental Studies of a New Bispecific Antibody, Pretargeting Enhancement System for Immunoscintigraphy in another window
Journal Articles

Development of New Multivalent-bispecific Agents for Pretargeting Tumor Localization and Therapy

Available to Purchase
Edmund A. Rossi, Robert M. Sharkey, William McBride, Habibe Karacay, Li Zeng, Hans J. Hansen, David M. Goldenberg, Chien-Hsing Chang
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (10): 3886s–3896s.
Published: 01 September 2003
View articletitled, Development of New Multivalent-bispecific Agents for Pretargeting Tumor Localization and Therapy
Open the PDF for Development of New Multivalent-bispecific Agents for Pretargeting Tumor Localization and Therapy in another window
Journal Articles

Optimizing Bispecific Antibody Pretargeting for Use in Radioimmunotherapy

Available to Purchase
Robert M. Sharkey, Habibe Karacay, Heidi Richel, William J. McBride, Edmund A. Rossi, Ken Chang, Dion Yeldell, Gary L. Griffiths, Hans J. Hansen, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (10): 3897s–3913s.
Published: 01 September 2003
View articletitled, Optimizing Bispecific Antibody Pretargeting for Use in Radioimmunotherapy
Open the PDF for Optimizing Bispecific Antibody Pretargeting for Use in Radioimmunotherapy in another window
Journal Articles

Pharmacokinetics and Dosimetry Studies for Optimization of Anti-Carcinoembryonic Antigen × Anti-Hapten Bispecific Antibody-mediated Pretargeting of Iodine-131-labeled Hapten in a Phase I Radioimmunotherapy Trial

Available to Purchase
Françoise Kraeber-Bodéré, Alain Faivre-Chauvet, Ludovic Ferrer, Jean-Philippe Vuillez, Pierre-Yves Brard, Caroline Rousseau, Isabelle Resche, Anne Devillers, Sophie Laffont, Manuel Bardiès, Ken Chang, Robert M. Sharkey, David M. Goldenberg, Jean-François Chatal, Jacques Barbet
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (10): 3973s–3981s.
Published: 01 September 2003
View articletitled, Pharmacokinetics and Dosimetry Studies for Optimization of Anti-Carcinoembryonic Antigen × Anti-Hapten Bispecific Antibody-mediated Pretargeting of Iodine-131-labeled Hapten in a Phase I Radioimmunotherapy Trial
Open the PDF for Pharmacokinetics and Dosimetry Studies for Optimization of Anti-Carcinoembryonic Antigen × Anti-Hapten Bispecific Antibody-mediated Pretargeting of Iodine-131-labeled Hapten in a Phase I Radioimmunotherapy Trial in another window
Journal Articles

Cure of Metastatic Human Colonic Cancer in Mice with Radiolabeled Monoclonal Antibody Fragments

Available to Purchase
Thomas M. Behr, Rosalyn D. Blumenthal, Stavros Memtsoudis, Robert M. Sharkey, Stefan Gratz, Wolfgang Becker, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (12): 4900–4907.
Published: 01 December 2000
View articletitled, Cure of Metastatic Human Colonic Cancer in Mice with Radiolabeled Monoclonal Antibody Fragments
Open the PDF for Cure of Metastatic Human Colonic Cancer in Mice with Radiolabeled Monoclonal Antibody Fragments in another window
Journal Articles

Studies on the Red Marrow Dosimetry in Radioimmunotherapy: An Experimental Investigation of Factors Influencing the Radiation-induced Myelotoxicity in Therapy with β-, Auger/Conversion Electron-, or α-Emitters

Available to Purchase
Thomas M. Behr, George Sgouros, Michael G. Stabin, Martin Béhé, Christa Angerstein, Rosalyn D. Blumenthal, Christos Apostolidis, Roger Molinet, Robert M. Sharkey, Lothar Koch, David M. Goldenberg, Wolfgang Becker
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (10): 3031s–3043s.
Published: 01 October 1999
View articletitled, Studies on the Red Marrow Dosimetry in Radioimmunotherapy: An Experimental Investigation of Factors Influencing the Radiation-induced Myelotoxicity in Therapy with β-, Auger/Conversion Electron-, or α-Emitters
Open the PDF for Studies on the Red Marrow Dosimetry in Radioimmunotherapy: An Experimental Investigation of Factors Influencing the Radiation-induced Myelotoxicity in Therapy with β-, Auger/Conversion Electron-, or α-Emitters in another window